The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from Baseline in 24-Hour Urine Calcium
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Calcium
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Albumin
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Albumin-Corrected Total Calcium
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Ionized Calcium
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Magnesium
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Phosphate
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in 25-Hydroxy (25-OH) Vitamin D results
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Serum Creatinine
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR; calculated)
Timeframe: Baseline up to 10 years (follow-up)
Change from Baseline in 24-Hour Urine Protein
Timeframe: Baseline up to 10 years (follow-up)
Incidence Rate of the Renal Events
Timeframe: Baseline up to 10 years (follow-up)
Incidence Rate of the Soft Tissue Calcifications (site)
Timeframe: Baseline up to 10 years (follow-up)
Incidence Rate of the Cataract
Timeframe: Baseline up to 10 years (follow-up)
Incidence Rate of the Bone Fractures (site)
Timeframe: Baseline up to 10 years (follow-up)
Incidence Rate of the Cardiovascular Events
Timeframe: Baseline up to 10 years (follow-up)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Baseline up to 10 years (follow-up)